Drug Profile
CD319 chimeric antigen T cell therapy - Wuhan Bio Raid Biotechnology
Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Wuhan Bio-Raid Biotechnology
- Developer Tongji Hospital; Wuhan Bio-Raid Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for clinical-Phase-Unknown development in Haematological-malignancies(Second-line therapy or greater) in China (Parenteral)
- 22 Dec 2017 Clinical trials in Haematological malignancies (Second-line therapy or greater) in China (Parenteral)